Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has met the enrollment target for its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine (ClinicalTrials.gov Identifier: NCT04639466).

旨在防止不断发展的SARS-CoV-2变体的多抗原疫苗-佐治亚州亚特兰大，2023年9月11日（GLOBE NEWSWIRE）-通过NewMediaWire-GeoVax Labs，Inc。（纳斯达克股票代码：GOVX），一家生物技术公司开发针对癌症和传染病的免疫疗法和疫苗，今天宣布，它已经达到了评估GEO-CM04S1的2期临床试验的入选目标，作为之前接受过辉瑞或Moderna mRNA疫苗（ClinicalTrials.gov标识符：NCT04639466）的健康患者的助推器。

The study is designed to evaluate the safety profile and immunogenicity of two GEO-CM04S1 dose levels administered as a COVID-19 vaccine booster among healthy individuals previously vaccinated with one of the FDA approved SARS-CoV-2 mRNA vaccines. The immunological responses measured throughout the study will include both the level of neutralizing antibodies against SARS-CoV-2 variants of concern and specific T cell responses.

该研究旨在评估先前接种FDA批准的SARS-CoV-2 mRNA疫苗之一的健康个体中作为COVID-19疫苗加强剂施用的两种GEO-CM04S1剂量水平的安全性和免疫原性。在整个研究中测量的免疫应答将包括针对所关注的SARS-CoV-2变体的中和抗体水平和特异性T细胞应答。

GEO-CM04S1 is a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose. GEO-CM04S1 encodes for both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce both antibody and T cell responses to those parts of the virus less likely to mutate over time.

GEO-CM04S1是基于GeoVax MVA病毒载体平台的下一代COVID-19疫苗，该平台支持以单剂量向免疫系统呈递多种疫苗抗原。GEO-CM04S1编码SARS-CoV-2的刺突（S）和核衣壳（N）抗原，并且专门设计用于诱导针对病毒的那些部分的抗体和T细胞应答，这些部分不太可能随时间突变。

The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of COVID-19. Vaccines of this format should not require frequent and repeated modification or updating. “We would like to thank everyone who partnered with us to complete this important clinical trial enrollment milestone, especially the study volunteers and research s.

免疫系统功能更广泛的参与旨在预防由不断出现的COVID-19变体引起的严重疾病。这种形式的疫苗不需要频繁和重复的修改或更新。“我们要感谢与我们合作完成这一重要的临床试验注册里程碑的每个人，特别是研究志愿者和研究人员。